China’s poultry farming accounts for 50% of the world’s poultry population, with about 17 billion birds slaughtered annually. In the livestock and poultry farming industry, the prevention and control of epidemics is always a top priority. Avian influenza 및 뉴캐슬병 are the “top killers” in the global poultry farming industry. Newcastle disease, as a serious threat to the health of poultry, has long brought substantial economic losses to farmers. The successful research and development of the Newcastle Disease Gene VII vaccine has forged a solid defense for the prevention and control of poultry disease and has become the dawn of the healthy development of the poultry farming industry.
With the continuous evolution of the Newcastle disease virus, the genotype VII strain has become the primary epidemic strain in recent years. It spreads fast and is highly pathogenic, and the control effect of traditional vaccines is not good. Once the poultry is infected with Newcastle disease, there will be dyspnea, diarrhea, neurological disorders, laying hens egg production decreasing significantly, young poultry mortality being very high, and so on, seriously affecting breeding efficiency. The Newcastle disease Genotype VII marker vaccine has been developed in response to this critical situation. The vaccine has excellent immunity against genotype VII Newcastle disease virus.
WIXBIO is collaborating with China’s most senior poultry research institute to launch the Newcastle disease Gene-VII marker inactivated vaccine. The vaccine has been licensed for sale in China and has received excellent customer feedback.
The technologies adopted in developing this vaccine:
1. Reverse Vaccinology technology platform
2.Homo-genotypic Vaccine
3. ND Negative Marker Vaccine and its accompanying diagnostic reagents
Highlights of the development of a marker vaccine for Newcastle disease:
- 이 백신의 특징은 낮은 독성, 높은 효율, 항원 일치성, 유전적 안정성, 고유 마커, 우수한 증식 성능입니다.
- 백신의 특징: 우수한 면역 반응, 바이러스 배출 감소, 높은 방어 효율.
- 지원 검사 제품: 간편하고 민감도가 높으며 처리량이 많아, 뉴캐슬병 VII형 마커 백신주에 의해 유도된 혈청 항체와 다른 뉴캐슬병 바이러스주를 구별할 수 있습니다.
- 정화 및 평가 가능: 이 기술 솔루션을 통해 뉴캐슬병 바이러스 유행 지역의 역병을 정화하고, 관련 백신 및 동물용 의약품 사용을 줄이며, 사육 비용을 절감할 수 있습니다.
최소 접종량과 통상 접종량으로 뉴캐슬병 VII형 마커 불활화 백신을 접종한 SPF 닭에서 생성된 항체는 La Sota 그룹보다 높았습니다.
뉴캐슬병 VII형 마커 불활화 백신 접종군의 바이러스 배출 검출률은 La Sota보다 낮았습니다.
ND 유전자 VII형 마커 불활화 백신을 접종한 그룹의 장기 내 ND 바이러스 검출률은 La Sota 그룹보다 낮았습니다.
WIXBIO 뉴캐슬병 유전자 VII형 마커 불활화 백신의 국제 시장 판권과 뉴캐슬병 유전자 VII형 마커 불활화 백신 생산 기술의 국제 시장 홍보 및 판매권을 확보했습니다. WIXBIO는 전 세계 동물 백신 파트너와 협력하여 동물 전염병을 예방·관리하고 최고 품질의 동물 보호 제품과 질병 솔루션을 공유하고자 합니다.
협력 방식은 다음과 같습니다:
독점 대리점: WIXBIO signs an exclusive agency agreement with the distributor in the fixed distribution area. The distributor with the agency right is responsible for completing the registration of the Newcastle disease Gene-VII marked inactivated vaccine in its agent country and forming sales after obtaining the registration certificate.
Technical cooperation: This plan applies to animal vaccine manufacturers. After signing the agreement, the property owner of Newcastle Disease Gene-VII labeled inactivated vaccine production technology will provide training and guidance to the partners on all relevant technologies, such as research and development, production, and quality inspection of the vaccine until the partners produce qualified products.
Clean up the Newcastle disease virus and create an epidemic-free zone: All parties sign an agreement, give full play to the advantages of official policies, strive for the financial support of government projects, build an inter-governmental cooperation project, establish an epidemic-free zone or farm by using the vaccines and technical solutions of the property owner, and establish a standard of epidemic free zone or farm through WHO certification and local official certification.
Recent progress in the development of Newcastle disease type VII marker vaccine series:
- Creation of live attenuated marker vaccine for Newcastle Disease (ND) gene type VII.
- Research and development of inactivated inactivated gene VII marker vaccine for Newcastle Disease
- Application technology of Newcastle disease gene VII marker vaccine and other products in disease purification.
